Gilead to snap up liver disease biotech CymaBay for $4.3B

Gilead is bet­ting $4.3 bil­lion on a biotech six months be­fore the FDA is ex­pect­ed to make an ap­proval de­ci­sion on its rare liv­er dis­ease drug can­di­date. The Cal­i­for­nia big biotech will pay cash to buy CymaBay Ther­a­peu­tics, the com­pa­nies said Mon­day morn­ing. The deal is for…#gilead #fda #expected #cymabay #seladelpar #pbc #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news